Watcher Forum
Would you like to react to this message? Create an account in a few clicks or log in to continue.


Welcome to Watcher Forum
 
HomeLatest imagesSearchRegisterLog in

 

 ENENEWS.COM Blocked? No luck yet!

Go down 
AuthorMessage
Guest
Guest




ENENEWS.COM Blocked? No luck yet! Empty
PostSubject: ENENEWS.COM Blocked? No luck yet!   ENENEWS.COM Blocked? No luck yet! I_icon_minitimeThu Oct 09, 2014 8:53 pm

Other links also, either load forever or..

So don't expect really truthful news on the storm and Fuku

ene.com
Forbidden
You don't have permission to access / on this server.
Server unable to read htaccess file, denying access to be safe
Additionally, a 403 Forbidden error was encountered while trying to use an ErrorDocument to handle the request.
Back to top Go down
Guest
Guest




ENENEWS.COM Blocked? No luck yet! Empty
PostSubject: US Patent No: US 20120251502 A1 THE VIRUS   ENENEWS.COM Blocked? No luck yet! I_icon_minitimeThu Oct 09, 2014 8:55 pm

US Patent No: US 20120251502 A1
Posted on October 9, 2014 by Soren DreierENENEWS.COM Blocked? No luck yet! Unknown5-150x150
Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
DESCRIPTION
RELATED APPLICATIONS
This application claims priority benefit of U.S. Provisional Application 61/108,175 filed 24 Oct. 2008; the contents of which are hereby incorporated by reference.
DEPOSIT STATEMENT
The invention provides the isolated human Ebola (hEbola) viruses denoted as Bundibugyo (EboBun) deposited with the Centers for Disease Control and Prevention (“CDC”; Atlanta, Ga., United States of America) on Nov. 26, 2007 and accorded an accession number 200706291. This deposit was not made to an International Depository Authority (IDA) as established under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, and is a non-Budapest treaty deposit. The deposited organism is not acceptable by American Type Culture Collection (ATCC), Manassas, Va., an International Depository Authority (IDA) as established under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. Samples of the stated Deposit Accession No. 200706291 will be made available to approved facilities for thirty years from the date of deposit, and for the lifetime of the patent issuing from, or claiming priority to this application.
FIELD OF THE INVENTION
The invention is related to compositions and methods directed to a novel species of human Ebola (hEbola) virus.
BACKGROUND OF THE INVENTION
The family Filoviridae consists of two genera, Marburgvirus and Ebolavirus, which have likely evolved from a common ancestor1. The genus Ebolavirus includes four species: Zaire, Sudan, Reston and Côte d’Ivoire (Ivory Coast) ebolaviruses, which have, with the exception of Reston and Côte d’Ivoire ebolaviruses, been associated with large hemorrhagic fever (HF) outbreaks in Africa with high case fatality (53-90%)2.
Viruses of each species have genomes that are at least 30-40% divergent from one another, a level of diversity that presumably reflects differences in the ecological niche they occupy and in their evolutionary history. Identification of the natural reservoir of ebolaviruses remains somewhat elusive, although recent PCR and antibody data suggest that three species of arboreal fruit bats may be carriers of Zaire ebolavirus3. No data has yet been published to suggest reservoirs for the Sudan, Reston and Côte d’Ivoire ebolavirus species. However, a cave-dwelling fruit bat has been recently implicated as a natural host for marburgvirus4, 5, supporting the hypothesis that different bat species may be the reservoir hosts for the various filoviruses.
Filovirus outbreaks are sporadic, sometimes interspersed by years or even decades of no apparent disease activity. The last new species of ebolavirus was discovered 14 years ago (1994), in Cote d’Ivoire (Ivory Coast), and involved a single non-fatal case, a veterinarian who performed an autopsy on an infected chimpanzee found in the Tai Forest6. No further disease reports have been associated with Côte d’Ivoire ebolavirus, in contrast to Zaire and Sudan ebolaviruses which have each caused multiple large outbreaks over the same time period.
In late November 2007, HF cases were reported in the townships of Bundibugyo and Kikyo in Bundibugyo District, Western Uganda. The outbreak continued through January 2008, and resulted in approximately 149 cases and 37 deaths2. Laboratory investigation of the initial 29 suspect-case blood specimens by classic methods (antigen capture, IgM and IgG ELISA) and a recently developed random-primed pyrosequencing approach identified this to be an Ebola HF outbreak associated with a new discovered ebolavirus species. These specimens were negative when initially tested with highly sensitive real-time RT-PCR assays specific for all known Zaire and Sudan ebolaviruses and Marburg viruses. This new species is referred to herein as “the Bundibugyo species”, abbreviated “EboBun”.
Accordingly, compositions and methods directed to the new Ebola virus species are described herein and the most closely related Ebola Ivory Coast species, which compositions and methods are useful for diagnosis and prevention of human Ebola virus infection; including related vaccine development, and prevention of hemorrhagic fever in a human population.
SUMMARY OF THE INVENTION
The present invention is based upon the isolation and identification of a new human Ebola virus species, EboBun. EboBun was isolated from the patients suffering from hemorrhagic fever in a recent outbreak in Uganda. The isolated virus is a member of the Filoviridae family, a family of negative sense RNA viruses. Accordingly, the invention relates to the isolated EboBun virus that morphologically and phylogenetically relates to known members filoviridae.
In one aspect, the invention provides the isolated EboBun virus deposited with the Centers for Disease Control and Prevention (“CDC”; Atlanta, Ga., United States of America) on Nov. 26, 2007 and accorded an accession number 200706291, as stated in the paragraph entitled “DEPOSIT STATEMENT” supra.
In another aspect, the invention provides an isolated hEbola EboBun virus comprising a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: a) a nucleotide sequence set forth in SEQ ID NO: 1; b) a nucleotide sequence that hybridizes to the sequence set forth in SEQ ID NO: 1 under stringent conditions; and c) a nucleotide sequence that has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the SEQ ID NO: 1. In another aspect, the invention provides the complete genomic sequence of the hEbola virus EboBun.
In a related aspect, the invention provides nucleic acid molecules isolated from EboBun, or fragments thereof.
In another aspect, the invention provides proteins or polypeptides that are isolated from the EboBun, including viral proteins isolated from cells infected with the virus but not present in comparable uninfected cells; or fragments thereof. In one embodiment of the present invention, the amino acid sequences of the proteins or polypeptides are set forth in SEQ ID NOS: 2-9 and 59, or fragments thereof.
In a related aspect, the invention provides an isolated polypeptide encoded by the nucleic acid molecule of the inventive hEbola EboIC (Sequence ID No. 10) virus described above.
In another aspect, the invention provides an isolated hEbola EboIC virus comprising a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: a) a nucleotide sequence set forth in SEQ ID NO: 10; b) a nucleotide sequence that hybridizes to the sequence set forth in SEQ ID NO: 10 under stringent conditions; and c) a nucleotide sequence that has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the SEQ ID NO: 10. In another aspect, the invention provides the complete genomic sequence of the hEbola virus EboIC.
Read More: Here
Back to top Go down
quietobserver
Super Elite
quietobserver


Posts : 2707
Reputation : 131
Join date : 2013-02-06

ENENEWS.COM Blocked? No luck yet! Empty
PostSubject: Re: ENENEWS.COM Blocked? No luck yet!   ENENEWS.COM Blocked? No luck yet! I_icon_minitimeThu Oct 09, 2014 10:21 pm

It's working fine now.

That marsh that used to be a NPP got close to a foot of rain with the last typhoon over the weekend. Its only a matter of time at this point. True this time last year, truer today.
Back to top Go down
Sponsored content





ENENEWS.COM Blocked? No luck yet! Empty
PostSubject: Re: ENENEWS.COM Blocked? No luck yet!   ENENEWS.COM Blocked? No luck yet! I_icon_minitime

Back to top Go down
 
ENENEWS.COM Blocked? No luck yet!
Back to top 
Page 1 of 1
 Similar topics
-
» No luck in trying to contact the watchmen
» Fukushima - epa change forthcoming
» ENENEWS links not working...Explosion, smoke at Indian Point nuclear plant north of NYC
» The West has lost control of the world and disaster awaits :We’re going to need a great of luck to avoid a nuclear catastrophe
» GOOP-OIL NOT SO GOOFY

Permissions in this forum:You cannot reply to topics in this forum
Watcher Forum :: Welcome! :: General Discussion-
Jump to: